Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E L Saenko

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
The Journal of Biological Chemistry|June 16, 1995
Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIIIJ F Healey, I M Lubin, H Nakai, et al.
Biokhimiia (Moscow, Russia)|October 1, 1989
[Protective effect rendered by human ceruloplasmin on erythrocytes in hepatocerebral dystrophy]E L Saenko, O V Skorobogat'ko, T I Mzhel'skaia, et al.
Vox Sanguinis|August 31, 2002
Molecular defects in coagulation Factor VIII and their impact on Factor VIII functionE L Saenko, N Ananyeva, D Kouiavskaia, et al.
The Journal of Biological Chemistry|June 1, 2000
Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689K Nogami, M Shima, K Hosokawa, et al.
Thrombosis and Haemostasis|February 12, 1999
Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chainR Laub, M Di Giambattista, P Fondu, et al.
Thrombosis and Haemostasis|February 12, 1998
Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitorsY Sawamoto, R Prescott, D Zhong, et al.
British Journal of Haematology|May 31, 2001
Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRM(-)) and G1948D (CRM(r))D David, E L Saenko, I M Santos, et al.
Immunological Investigations|March 1, 1994
Modulatory effects of ceruloplasmin on lymphocytes, neutrophils and monocytes of patients with altered immune statusE L Saenko, O V Skorobogat'ko, P Tarasenko, et al.
Blood|May 15, 1997
The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study GroupsR Prescott, H Nakai, E L Saenko, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 12, 2002
Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their actionE L Saenko, N M Ananyeva, D V Kouiavskaia, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
The Journal of Biological Chemistry|June 16, 1995
Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIIIJ F Healey, I M Lubin, H Nakai, et al.
Biokhimiia (Moscow, Russia)|October 1, 1989
[Protective effect rendered by human ceruloplasmin on erythrocytes in hepatocerebral dystrophy]E L Saenko, O V Skorobogat'ko, T I Mzhel'skaia, et al.
Vox Sanguinis|August 31, 2002
Molecular defects in coagulation Factor VIII and their impact on Factor VIII functionE L Saenko, N Ananyeva, D Kouiavskaia, et al.
The Journal of Biological Chemistry|June 1, 2000
Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689K Nogami, M Shima, K Hosokawa, et al.
Thrombosis and Haemostasis|February 12, 1999
Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chainR Laub, M Di Giambattista, P Fondu, et al.
Thrombosis and Haemostasis|February 12, 1998
Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitorsY Sawamoto, R Prescott, D Zhong, et al.
British Journal of Haematology|May 31, 2001
Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRM(-)) and G1948D (CRM(r))D David, E L Saenko, I M Santos, et al.
Immunological Investigations|March 1, 1994
Modulatory effects of ceruloplasmin on lymphocytes, neutrophils and monocytes of patients with altered immune statusE L Saenko, O V Skorobogat'ko, P Tarasenko, et al.
Blood|May 15, 1997
The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study GroupsR Prescott, H Nakai, E L Saenko, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 12, 2002
Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their actionE L Saenko, N M Ananyeva, D V Kouiavskaia, et al.
Pageof 6